Procognia Ltd., the Israel based leading glycobiology and glycoanalysis company, is producing its new generation of the GlycoScope, the Multi Pad product with Scienion’s sciFLEXARRAYER technology.

Many new drugs currently entering the market are biological drugs, and most of them include glycoproteins. Understanding and analyzing the glycosylation structure of these glycoproteins during development and manufacturing is crucial for the successful functioning of the drug in the human body, as they may affect the drug's activity, immunogenicity, and pharmacokinetics.

Procognia’s GlycoScope platform is designed specifically for pharmaceutical companies and research labs. It focuses on the identification of glycosylation structure of glycoproteins during the research, development, and production phases of biological drugs, and can also be used for other applications such as stem cell research, vaccine development, and more. The microarray technology platform based on lectins as capture molecules enables the analysis of dozens of samples in parallel, in a simple, rapid test, with patented automatic data analysis software for accurate, same day results.

Procognia Ltd.